Protocol Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicentre,
International Study of Durvalumab and Domvanalimab (AB154) as Sequential Therapy in
Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer
Whose Disease has not Progressed Following Definitive, Platinum-based Concurrent
Chemoradiation Therapy (PACIFIC 8)
Protocol Number: D9075C00001